^
    Back
    Association details:
    Biomarker:TNFRSF8 expression
    Cancer:Acute Myelogenous Leukemia
    Drug:Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Peripheral T-cell Lymphoma)
    New
    Excerpt:
    ADCETRIS is a CD30-directed antibody-drug conjugate indicated for treatment of adult patients with:...Previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

    Excerpt:
    ...AML blasts must express CD30 (>/=10% expression as assessed by flow-cytometry or 2+ expression by immunohistochemistry) (whenever possible CD30 expression will be assessed by both methods) 3....
    Trial ID:
    NCT02096042
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Brentuximab Vedotin + Re-induction Chemotherapy for AML

    Excerpt:
    ...- CD30 expressing AML...
    Trial ID:
    NCT01830777
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Cancer
    Title:

    A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia

    Excerpt:
    The median overall survival was 9.5 months, with a median disease-free survival of 6.8 months observed among responders….The combination of BV with MEC was found to be safe in patients with CD30-expressing R/R AML…
    Secondary therapy:
    cytarabine + etoposide IV + mitoxantrone
    DOI:
    10.1002/cncr.32657
    Trial ID:
    NCT01830777